Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 57.8% in February

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 51,300 shares, a growth of 57.8% from the February 13th total of 32,500 shares. Based on an average daily volume of 66,900 shares, the short-interest ratio is currently 0.8 days. Approximately 1.3% of the shares of the stock are sold short.

Analyst Ratings Changes

MNPR has been the subject of several research reports. HC Wainwright lifted their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Piper Sandler began coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $72.00 price objective for the company.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. purchased a new position in shares of Monopar Therapeutics in the fourth quarter valued at $3,694,000. Janus Henderson Group PLC purchased a new stake in shares of Monopar Therapeutics during the fourth quarter worth about $23,435,000. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics in the fourth quarter worth about $45,000. Geode Capital Management LLC boosted its holdings in Monopar Therapeutics by 174.4% in the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after purchasing an additional 24,530 shares during the last quarter. Finally, RA Capital Management L.P. purchased a new stake in Monopar Therapeutics during the 4th quarter worth approximately $11,247,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Price Performance

MNPR stock traded up $3.19 during midday trading on Monday, hitting $32.94. The stock had a trading volume of 13,869 shares, compared to its average volume of 360,329. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The firm has a market cap of $200.97 million, a PE ratio of -16.72 and a beta of 1.18. The company’s 50-day moving average price is $35.77 and its 200 day moving average price is $21.54.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.